Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer
August 6th 2022The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with chemotherapy for HER2-low patients with both hormone receptor (HR)–positive and HR-negative disease.
Read More
Young Adults With SCD Show Better Hydroxyurea Adherence Than Children, Adolescents
August 6th 2022With adherence estimated at less than 50% in children, adolescents, and young adults, a recent study stresses the importance of treatment adherence for patients with sickle cell disease receiving hydroxyurea and the benefit for those who do.
Read More
Obesity, Physical Inactivity Linked With Higher Risk for Activity Limits in Asthma
August 5th 2022Patients with asthma and all types of obesity, or with all types of obesity and physical inactivity, have an increased risk for limited activity of daily living, according to the results of a recent study.
Read More
Advocate Addresses Factors Physicians Should Consider in Managing Hidradenitis Suppurativa
August 5th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on the need for awareness among physicians and patients on the clinical features of HS in regard to both physical and psychosocial burdens.
Watch
Pharmaceutical Research and Manufacturers of America (PhRMA) is threatening swift retaliation if a reconciliation package that includes drug pricing is passed; New York health officials urge polio vaccinations after polio virus was found in 7 wastewater samples; conjoined twins in Brazil were separated via surgery using virtual reality.
Read More
Three CAR T-Cell Trials, 2 Outcomes, for Second-line LBCL Therapy
August 4th 2022Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.
Read More
Phase 3 Study: Zanubrutinib Improves PFS Over Chemoimmunotherapy in Untreated CLL, SLL
August 4th 2022The findings, coming from the phase 3 SEQUOIA study, found that the next-generation, selective Bruton tyrosine kinase inhibitor had superior efficacy versus chemoimmunotherapy and demonstrated an acceptable safety profile among 600 older patients with comorbidities.
Read More
NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression
August 4th 2022Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
Read More
President Joe Biden signed an executive order to help people travel between states for an abortion; Eli Lilly was ordered to pay $61 million after allegedly underpaying the Medicaid drug rebate program; CVS plans to acquire or take a stake in a primary care industry by the end of 2022.
Read More
Federal Holidays, Daylight Savings Have Effect on Sleep Duration, Consistency
August 4th 2022A retrospective observational study found that many US federal holidays and holiday eves were associated with changes in sleep duration, decreases in sleep consistency, and later sleep onset and offset.
Read More
For Early-Stage cHL Survivors, CVD Has Surpassed Neoplasms as Leading Cause of Death
August 3rd 2022Cardiovascular disease (CVD) has, over time, becoming the leading cause of death for patients with early-stage classic Hodgkin lymphoma (cHL), surpassing the risk of death from cHL and other cancers.
Read More